TY - JOUR
T1 - Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis
T2 - A case report and review of the literature
AU - Sikander, Ailawadhi
AU - Sadashiv, Shenoy
AU - Ronald, Sham
AU - Milind, Javle
PY - 2005/12
Y1 - 2005/12
N2 - Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.
AB - Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.
KW - Chemoembolization
KW - Hepatocellular carcinoma
KW - Portal vein thrombosis
UR - http://www.scopus.com/inward/record.url?scp=29044433658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29044433658&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000158488.36371.50
DO - 10.1097/01.coc.0000158488.36371.50
M3 - Review article
C2 - 16317281
AN - SCOPUS:29044433658
SN - 0277-3732
VL - 28
SP - 638
EP - 639
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 6
ER -